Sebi mulls expanding scope of unpublished price-sensitive information

To enhance transparency in market disclosures, Sebi is looking to broaden the scope of Unpublished Price Sensitive Information (UPSI) by including proposed fundraising activities, restructuring plans, and one-time bank settlements.

In its consultation paper, Sebi has proposed that only agreements, including shareholder, joint venture and family settlement, that affect the management and control of the firm and are known to the firm should be considered price-sensitive and included in the illustrative list of events under the definition of UPSI.

Additionally, key developments in corporate insolvency proceedings, such as initiation or approval of resolution plans by the tribunal, should be disclosed as potentially price-sensitive.

If a forensic audit is launched or concluded for issues like fund misappropriation or financial misstatements, it should be disclosed as price-sensitive.

Also ReadFPIs withdraw nearly Rs 20,000 cr from equities in last 5 trading sessions

The proposed changes to Sebi’s definition of UPSI are aimed at increasing regulatory clarity and consistency.

In the constitution paper, Sebi suggested including fundraising proposed to be undertaken in the definition of UPSI.

Currently, the decision concerning fundraising proposed to be undertaken is not included in the definition at present.

The regulator has proposed the inclusion of restructuring plans, one-time bank settlements and other significant financial restructurings as UPSI.

Sebi has also proposed that actions by regulatory or judicial bodies against a company or its key personnel if involving significant enforcement, fines, penalties, or other sanctions, should be considered price-sensitive and classified as UPSI.

Among others, the regulator suggested that outcomes of major litigations or disputes that could affect a company’s operations or finances, along with any major contracts or orders awarded to the company (or significant amendments or terminations) outside regular business activities, should be disclosed as UPSI due to their potential impact on financial performance.

Further, the granting, withdrawal, or suspension of essential licences or approvals should be disclosed, as such events could significantly affect company operations.

The Securities and Exchange Board of India (Sebi) has sought public comments on the proposals by November 30. 

 » Read More

Related Articles

Q3FY25 Results: Thyrocare reports 30 percent rise in profit; Revenue stood at Rs 165.9 Crore

Thyrocare on Thursday announced its financial results for the quarter and nine months ended December 31, 2024. According to the company’s statement, the diagnostics major reported revenue of Rs. 165.9 Cr in Q3FY25 with a growth of 23 percent YoY. According to the company’s statement, Thyrocare’s consolidated revenue increased by 23% year-over-year (YoY) with Pathology

Gold prices soar to new peak of Rs 82,900 per 10 gm; silver drops by Rs 500

Gold prices rose Rs 170 to hit a fresh record high of Rs 82,900 per 10 grams in the national capital on Thursday amid a positive global trend, according to the All India Sarafa Association. The precious metal had closed at Rs 82,730 per 10 grams on Wednesday. In about one year, the precious metal

Good news for taxpayers! Govt removes THESE difficulties to ensure more tax cases are settled – Check details!

Good news for taxpayers! The Finance Ministry has made some changes to the Direct Tax Vivad Se Vishwas Scheme, 2024, removing “difficulties” that arose due to certain situations for taxpayers. This update in the scheme will bring relief to taxpayers who wanted to apply for the scheme but could not do so earlier. “CBDT…makes the

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Q3FY25 Results: Thyrocare reports 30 percent rise in profit; Revenue stood at Rs 165.9 Crore

Thyrocare on Thursday announced its financial results for the quarter and nine months ended December 31, 2024. According to the company’s statement, the diagnostics major reported revenue of Rs. 165.9 Cr in Q3FY25 with a growth of 23 percent YoY. According to the company’s statement, Thyrocare’s consolidated revenue increased by 23% year-over-year (YoY) with Pathology

Gold prices soar to new peak of Rs 82,900 per 10 gm; silver drops by Rs 500

Gold prices rose Rs 170 to hit a fresh record high of Rs 82,900 per 10 grams in the national capital on Thursday amid a positive global trend, according to the All India Sarafa Association. The precious metal had closed at Rs 82,730 per 10 grams on Wednesday. In about one year, the precious metal

Good news for taxpayers! Govt removes THESE difficulties to ensure more tax cases are settled – Check details!

Good news for taxpayers! The Finance Ministry has made some changes to the Direct Tax Vivad Se Vishwas Scheme, 2024, removing “difficulties” that arose due to certain situations for taxpayers. This update in the scheme will bring relief to taxpayers who wanted to apply for the scheme but could not do so earlier. “CBDT…makes the

Johnnie Walker-maker United Spirits posts Q3 profit decline of 4.29% to Rs 335 crore, revenue up 11.06% YoY

United Spirits, which makes Smirnoff vodka, on Thursday reported a profit of Rs 335 crore for the third quarter of FY25, posting a decline of 4.29 per cent in comparison to Rs 350 crore during the corresponding quarter of previous financial year. It posted revenue from operations at Rs 7,732 crore, reporting a growth of

Q3FY25: Mankind Pharma’s revenue up by 24 percent to Rs 3,230 Crore; Profit at Rs 380 crore

Pharma major Mankind Pharma on Thursday reported its financial results for the third quarter and nine months ended 31 st December 2024. The company reported revenue from Operations at Rs. 3,230 Cr, up by 24% YoY and domestic revenue at INR 2,773 Cr, up 17%, Exports at INR 457 Cr, up 121% YoY. The company’s